Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
1 other identifier
interventional
3,000
1 country
10
Brief Summary
The GLITTER study is comprised of four key components: Team, Technology, Education, and Peer Resources. The aim of the GLITTER Study is to improve the metabolic control rate in patients with type 1 diabetes through a comprehensive management approach.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jan 2025
Typical duration for not_applicable
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2025
CompletedFirst Submitted
Initial submission to the registry
July 24, 2025
CompletedFirst Posted
Study publicly available on registry
July 31, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2028
July 31, 2025
September 1, 2024
3 years
July 24, 2025
July 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in HbA1c
The primary outcome is the Change in Glycated Hemoglobin A1C (HbA1c). HbA1c is a physiological marker of the percentage of red blood cells that have glycated (bonded with a sugar). HbA1c is used to measure changes in average blood sugar over the past three months.
Trough study completion, an average of 1 year
Secondary Outcomes (19)
Percentage of patients using continuous glucose monitors
Trough study completion, an average of 1 year
Percentage of patients using insulin pump
Trough study completion, an average of 1 year
Diabetes-related complications
Trough study completion, an average of 1 year
Urine Albumin-to-Creatinine Ratio
Trough study completion, an average of 1 year
Change in titer of autoantibodies
Trough study completion, an average of 1 year
- +14 more secondary outcomes
Study Arms (1)
T1D Patients
OTHERAll patients diagnosed with type 1 diabetes of all ages.
Interventions
The GLITTER comprehensive management represents a management approach that effectively combines multidisciplinary professional team care, diabetes technology empowerment, structured education steering, and peer support.
Eligibility Criteria
You may qualify if:
- \. Patients with type 1 diabetes of all age groups, regardless of disease duration.
- The diagnosis criteria for type 1 diabetes are met by fulfilling any one point from the first two criteria plus any one point from the third criterion.
- Clinically diagnosed as Type 1 Diabetes by a specialist physician.
- Meet any one of the following criteria:
- A. Age of onset \<15 years B. No obesity at the time of onset C. diabetic ketoacidosis onset D. Maximum random C-peptide \<200 pmol/L
- Meet any one of the following criteria:
- A. Initiation and continuation of insulin therapy after diagnosis (excluding pancreas or islet transplantation) B. Positive for islet cell antibodies
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (10)
Department of Endocrinology and Metabolism, Peking University People's Hospital
Beijing, Beijing Municipality, China
Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Department of Endocrinology and Metabolism, the Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University
Shenzhen, Guangdong, China
Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Luoyang, Henan, China
Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University
Changsha, Hunan, 410011, China
Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, 210029, China
Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University
Chengdu, Sichuan, China
Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 24, 2025
First Posted
July 31, 2025
Study Start
January 1, 2025
Primary Completion (Estimated)
December 31, 2027
Study Completion (Estimated)
March 1, 2028
Last Updated
July 31, 2025
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share